PDSB News and Press, PDS Biotechnology Corporation From 04/20/22

FLORHAM PARK, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary ...

PDS Biotechnology (NASDAQ:PDSB) said that on April 18 it received $1.2M from the net sale of tax benefits to an unrelated, profitable New Jersey corporation as the company participated in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for State fi...

FLORHAM PARK, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary ...

FY2021 Results Were Within Expectations. PDS Biotech reported 4Q21 loss of $6.3 million or $(0.23) per share, bringing the FY2021 loss to $16.9 million or $(0.66) per share. On its quarterly conference call, the company discussed pipeline developments in several HPV-positive cancer trials, pre...

PDS Biotechnology Corporation (PDSB) Q4 2021 Results Earnings Conference Call March 31, 2022, 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Offi...

PDS Biotechnology press release (NASDAQ:PDSB): FY GAAP EPS of -$0.66 beats by $0.05. The company’s cash balance as of December 31, 2021 was $65.2M. Based on the company’s available cash resources and cash flow projections, the company believes this balance is sufficient to fund ...

FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...

PDS Biotechnology (NASDAQ:PDSB) is scheduled to announce Q4 earnings results on Thursday, March 31st, before market open. The consensus EPS Estimate is -$0.25 (+71.9% Y/Y) and the consensus Revenue Estimate is $0M. Over the last 3 months, EPS estimates have seen 0 upward revisions a...

ACTG, AFMD, OTCPK:BRPHF, OTCQX:CBWTF, CLSN, GOED, LTRY, NNDM, NNOX, PDSB, PLX, PTR, TRVN, WBA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...